Can HbA1c remain normal in early insulin resistance because compensatory hyperinsulinemia maintains average glucose?

The physiological progression from insulin sensitivity to metabolic dysfunction is characterized by a silent period where traditional markers of glycemic control, such as HbA1c, fail to reflect underlying pathology. In early insulin resistance, the body preserves euglycemia through a robust compensatory response that masks metabolic strain.

Clinical evidence and HbA1c sensitivity

HbA1c measures the percentage of glycated hemoglobin, providing a weighted average of blood glucose levels over the preceding 8–12 weeks. While highly effective for diagnosing and monitoring type 2 diabetes, its sensitivity for early-stage insulin resistance is limited.

• Studies utilizing the Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) consistently identify individuals with significant insulin resistance who maintain "normal" HbA1c levels (typically <5.7% or even <6.0%).
• Research indicates that even when HbA1c is within the reference range, individuals with underlying insulin resistance exhibit elevated risks for subclinical atherosclerosis, coronary artery calcium, and metabolic syndrome.
• In one cohort study, HbA1c was found to be a lagging indicator, only rising significantly once the pancreas could no longer produce enough insulin to overcome peripheral resistance.

Mechanistic explanations of glucose maintenance

The maintenance of normal average glucose levels during early metabolic dysfunction is driven by compensatory hyperinsulinemia, a physiological "overdrive" state.

• Beta-cell adaptation: Pancreatic beta cells respond to peripheral resistance (primarily in skeletal muscle and liver) by increasing insulin secretion. This is achieved through enhanced glucokinase activity and increased beta-cell mass via hypertrophy and proliferation.
• Reduced insulin clearance: Beyond secretion, the body often reduces the insulin clearance rate (ICR), particularly in the liver. This ensures that circulating insulin remains elevated for longer periods to facilitate glucose uptake.
• Signaling override: By increasing the concentration of insulin, the body forces glucose into cells despite impaired receptor signaling. This effectively "masks" the resistance by keeping systemic glucose—and thus hemoglobin glycation—at healthy levels.

Clinical implications

Relying solely on HbA1c can lead to a false sense of security regarding metabolic health. In patients with risk factors like central adiposity or family history, measuring fasting insulin alongside glucose to calculate HOMA-IR (Fasting Insulin × Fasting Glucose / 405) provides a more accurate assessment of the metabolic effort required to maintain those glucose levels.

Bottom line

HbA1c often remains normal in early insulin resistance because compensatory hyperinsulinemia—driven by increased beta-cell output and reduced insulin clearance—successfully maintains average glucose levels. This means metabolic deterioration can be well underway long before it is reflected in standard glycation or glucose tests.